What is dengue shock syndrome?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: August 16, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dengue Shock Syndrome Definition

Dengue shock syndrome (DSS) is a severe, life-threatening complication of dengue infection characterized by sudden vascular permeability leading to profound intravascular volume depletion, circulatory collapse, and shock. 1

Clinical Characteristics

DSS represents the most severe manifestation of dengue hemorrhagic fever and occurs when plasma leakage becomes so profound that it results in:

  • Circulatory failure with hypotension
  • Narrow pulse pressure (<20 mmHg) - with severe DSS defined as pulse pressure <10 mmHg 2
  • Signs of tissue hypoperfusion including:
    • Capillary refill time ≥3 seconds
    • Cold, clammy extremities
    • Weak or absent peripheral pulses
    • Altered mental status
    • Oliguria

Pathophysiology

The fundamental mechanism involves a transient capillary leak syndrome 3. When T cells attack dengue-infected cells, they release cytokines that cause sudden vascular permeability 1. This endothelial dysfunction leads to massive plasma leakage from the intravascular space into the interstitial compartment, resulting in:

  • Profound hypovolemia despite total body fluid overload
  • Hemoconcentration (elevated hematocrit)
  • Thrombocytopenia
  • Potential hemorrhagic manifestations

Clinical Phases and Timing

DSS typically occurs during the critical phase of dengue infection, usually around days 3-7 of illness 4. The disease progresses through three phases:

  1. Febrile phase (days 1-7): High fever, headache, myalgia, arthralgia
  2. Critical phase (days 3-7): Plasma leakage, shock development
  3. Recovery phase: Reabsorption of extravasated fluid

Severity Classification

Severe DSS is distinguished by pulse pressure <10 mmHg, while moderate DSS has pulse pressure between 10-20 mmHg 2. This distinction has important treatment implications, particularly regarding colloid use.

Key Clinical Pitfall

DSS can present with recurrent shock episodes in approximately 34% of cases 3. Risk factors for recurrent shock include:

  • Younger age
  • BMI ≥25 kg/m²
  • Day of illness ≤5 at presentation
  • Prior COVID-19 infection 5

Associated Complications

Beyond shock, DSS may be complicated by 5:

  • Severe hemorrhage (10% of cases)
  • Hepatic impairment (22%)
  • Acute kidney injury (2.8%)
  • Cardiac impairment (1.6%)
  • Neurological impairment (1.5%)

The critical distinguishing feature of DSS from other forms of dengue is the presence of circulatory collapse requiring urgent fluid resuscitation, with the pathognomonic finding being the transient but severe capillary leak leading to hypovolemic shock 6, 3.

Related Questions

What are the clinical differences between compensated and decompensated dengue shock syndrome?
What is the pathophysiology of dengue shock syndrome?
For a pediatric dengue patient who received an initial crystalloid bolus of 10 cc/kg, the order is to give a total of 7 cc/kg over 2 hours using hydroxyethyl starch (HES) for two‑thirds of the volume and Plasma‑Lyte for one‑third, but only one bag of HES is available; how should the fluid regimen be adjusted?
What is the appropriate management for a 26-year-old female with dengue shock syndrome who is intubated for severe dyspnea and remains hypotensive and tachycardic despite an initial fluid challenge?
Is compensated dengue shock managed with isotonic crystalloid at 10 ml per kilogram per hour?
How do the dosing guidelines differ between lidocaine and bupivacaine for local anesthesia?
Can choline supplementation cause constipation?
What is the recommended loading dose of hydrocortisone for pediatric patients?
What is renal osteodystrophy, including its pathophysiology, clinical features, laboratory abnormalities, and management?
What percentage of solid breast masses identified on ultrasound are benign versus malignant when intraductal papillomas are excluded?
What is the recommended dosage of slow‑release methylphenidate (e.g., Concerta, Ritalin LA, Metadate CD) for an adult with severe attention‑deficit/hyperactivity disorder characterized by inattentiveness, impulsivity, and executive dysfunction, who rapidly adapts to dose and has bipolar II disorder with depressive episodes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.